

Study: ENGOT-ov63/ NIRVANA-1

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery.

MaNGO Sites

Prov	City	Site	Principal Investigator	Active
CN	Cuneo	Ospedale Carle	Marcella Occelli	Yes
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	Yes
MB	Monza	Ospedale San Gerardo	Andrea A. Lissoni	Yes
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	Yes
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi *	Yes
SO	Sondrio	Ospedale di Sondrio	Alessandro Bertolini	Yes
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	No

* MaNGO Principal Investigator